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Abstract
The mammalian target of rapamycin (mTOR) modulates immune responses and cellular proliferation. The objective of this
study was to assess whether inhibition of mTOR with rapamycin modifies disease severity in two experimental murine
models of house dust mite (HDM)-induced asthma. In an induction model, rapamycin was administered to BALB/c mice
coincident with nasal HDM challenges for 3 weeks. In a treatment model, nasal HDM challenges were performed for 6 weeks
and rapamycin treatment was administered during weeks 4 through 6. In the induction model, rapamycin significantly
attenuated airway inflammation, airway hyperreactivity (AHR) and goblet cell hyperplasia. In contrast, treatment of
established HDM-induced asthma with rapamycin exacerbated AHR and airway inflammation, whereas goblet cell
hyperplasia was not modified. Phosphorylation of the S6 ribosomal protein, which is downstream of mTORC1, was increased
after 3 weeks, but not 6 weeks of HDM-challenge. Rapamycin reduced S6 phosphorylation in HDM-challenged mice in both
the induction and treatment models. Thus, the paradoxical effects of rapamycin on asthma severity paralleled the activation
of mTOR signaling. Lastly, mediastinal lymph node re-stimulation experiments showed that treatment of rapamycin-naive T
cells with ex vivo rapamycin decreased antigen-specific Th2 cytokine production, whereas prior exposure to in vivo
rapamycin rendered T cells refractory to the suppressive effects of ex vivo rapamycin. We conclude that rapamycin had
paradoxical effects on the pathogenesis of experimental HDM-induced asthma. Thus, consistent with the context-
dependent effects of rapamycin on inflammation, the timing of mTOR inhibition may be an important determinant of
efficacy and toxicity in HDM-induced asthma.
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Introduction
Rapamycin (Sirolimus, RapamuneH) is a macrolide product of
Streptomyces hygroscopius that was initially discovered in a soil
sample from Easter Island (Rapa Nui) in the early 1970s [1].
Rapamycin inhibits signaling by targeting the mammalian target
of rapamycin (mTOR) with resultant immunosuppression and
inhibition of cellular proliferation. Rapamycin is in clinical use for
the prevention of kidney transplant rejection and has also been
investigated as a treatment for tuberous sclerosis and lymphangio-
leiomyomatosis [2]. Similarly, rapamycin-eluting coronary artery
stents have been developed to prevent re-stenosis [3,4]. Rapamy-
cin has also been proposed as a candidate treatment for asthma.
Consistent with this, the ability of rapamycin-derivatives to inhibit
asthma has been investigated in experimental animal models. The
rapamycin derivative, 32-deoxorapamycin (SAR 943), was shown
to be as effective as corticosteroids in inhibiting eosinophilic and
lymphocytic airway inflammation, Th2 cytokine production,
epithelial cell proliferation, goblet cell hyperplasia, and airway
hyperreactivity in a murine model of ovalbumin (OVA)-induced
asthma [5]. In contrast, intratracheal administration of 32-
deoxorapamycin prior to a single OVA challenge in sensitized
Brown-Norway rats, did not inhibit the number of bronchoalveo-
lar lavage fluid eosinophils, lymphocytes or neutrophils, nor did it
suppress airway hyperreactivity [6]. In another Brown-Norway rat
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25model, repeated oral administration of 32-deoxyrapamycin to
sensitized animals that had already begun to receive multiple
OVA challenges, inhibited airway smooth muscle and epithelial
cell proliferation and reduced the number of CD4+ T cells, but did
not inhibit airway hyperreactivity or pulmonary eosinophilia [7].
Thus, previous studies report conflicting results regarding the
utility of mTOR inhibitors for the treatment of asthma.
Here, we sought to define the role of mTOR signaling on the
pathogenic manifestations of asthma using a clinically relevant
house dust mite (HDM)-induced model of murine disease. We
selected HDM to induce airway disease because it is an important
environmental aeroallergen that has been identified as a risk factor
for persistent asthma in human subjects [8,9]. HDM has
a heterogeneous composition that includes multiple proteins and
lipopolysaccharide, which induces airway inflammation via both
allergic and non-allergic pathways [10,11,12]. These pathways
include toll-like receptor 4 signaling in airway epithelial cells,
which activates both innate and adaptive immune responses [13].
We show that inhibition of mTOR signaling by rapamycin has
paradoxical effects on the manifestations of HDM-induced
asthma. Inhibition of mTOR signaling with rapamycin prior to
the induction of asthma effectively suppressed airway inflamma-
tion, goblet cell hyperplasia and airway hyperreactivity, whereas
inhibition of mTOR signaling in established asthma exacerbated
airway inflammation and airway hyperreactivity, but did not
modify HDM-induced increases in goblet cell hyperplasia.
Methods
Murine Models of Experimental House Dust Mite-induced
Asthma
Female Balb/c mice were purchased from Jackson Laboratories
(Bar Harbor, Maine). Asthma was induced by daily intranasal
administration of HDM (Dermatophagoides pteronyssinus) (25 mg) or
saline in a volume of 12 ml for 5 days each week [8]. In the
induction model, mice received rapamycin (3 mg/kg) or vehicle
(Phosal 50 PGH), by gavage daily, 5 days per week for 3 weeks
concurrent with administration of nasal HDM. In the treatment
model, mice received daily nasal HDM for 6 weeks and were
treated with rapamycin (3 mg/kg) or vehicle (Phosal 50 PGH), by
gavage daily, 5 days per week, during weeks 4 through 6. HDM
was purchased from Greer Laboratories (Lenoir, NC), while the
rapamycin oral solution was from Wyeth (Philadelphia, PA) and
Phosal 50 PGH was from the American Lecithin Company
(Oxford, CT). All experimental protocols (Protocols H-0210 and
H-0244) were approved by the Animal Care and Use Committee
of the National Heart, Lung, and Blood Institute. Results are
representative of two independent experiments for each model.
Bronchoalveolar Lavage and Lung Histopathologic
Examination
Bronchoalveolar lavage (BAL) was performed utilizing three
instillations of ice cold PBS (0.5 ml). Red blood cells present in
BAL fluid (BALF) were lysed using ACK buffer (2 min at 4uC),
followed by re-suspension of cells in 0.3 ml RPMI-1640 with 20%
fetal bovine serum. The total number of BALF cells were counted
using a hemocytometer. The differential cell counts were
performed on Diff-Quick-stained cytospin slides (Siemens Health-
care Diagnostics, Deerfield, IL). For histopathological examina-
tion, lungs were inflated to a pressure of 25 cm of H20 and fixed in
10% formalin for 24 h. Lungs were then dehydrated through
gradient ethanol prior to embedding in paraffin. Sagittal sections
were cut at a thickness of 5 mm and stained with hematoxylin and
eosin or periodic acid Schiff (PAS). Representative histology
images were selected by one of the authors who was blinded to the
identity of the groups. Quantification of goblet cell hyperplasia was
performed as previously described [14]. Briefly, all the airways
present (large (conducting), medium (central), and small (distal))
within representative lung sections were analyzed and the number
of airways containing PAS-positive cells were recorded. Goblet cell
hyperplasia is presented as the percentage of airways containing
PAS-positive cells. The number of airways inspected in each
animal is also presented.
Quantitative RT-PCR
Lungs were minced prior to storage in RNAlaterH (Applied
Biosystems Inc., Foster City, CA) at 270uC. Total RNA was
subsequently isolated using the lipid tissue kit from Qiagen (Qiagen
Inc,Valencia,CA)andon-columnDNasetreatmentwasperformed
using RNase-Free DNase from Qiagen. Reverse transcription was
performed utilizing random hexamer primers and High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City,
CA). PCR was performed utilizing the TaqMan Universal PCR
Master Mix and the following FAM dye-labeled TaqmanH MGB
probes; IL-4: Mm00445259_m1, IL-10: Mm00439614_m1, IL-13:
Mm00434204_m1, IL-17a: Mm00439618_m1, Muc5Ac:
Mm01276735_m1, Clca3: Mm00489959_m1, CCL7:
Mm00443113_m1, CCL11: Mm00441238_m1, CCL17:
Mm00516136_m1, CCL24: Mm00444701_m1 and 18S:
Hs99999901_s1. One mg of cDNA was used as a template. and
samples were amplified utilizing the 7500 Real Time PCR System
running Sequence Detector version 2.1 software (ABI systems,
Foster City, CA). Gene expression was quantified relative to the
expression of 18S mRNA using the control sample as calibrator to
calculatethedifferenceinCtvalues(DDCt)andresultsarepresented
as relative mRNA expression.
HDM-specific Re-stimulation of Mediastinal Lymph Node
Cultures and Measurement of Th2 Cytokine Production
Mediastinal lymph nodes were removed, disrupted by gentle
pressure with a syringe plunger and passed through a 100 mm
strainer to yield single cell suspensions [15]. Following lysis of red
blood cells with ACK buffer, mediastinal lymph node cells were
suspended in RPMI 1640 medium containing 10% fetal calf
serum, penicillin (50 units/ml), streptomycin (50 mg/ml), and L-
gluamine (2 mM) and 4610
6 cells per well were cultured in 96-
well plates with ‘‘U’’-shaped bottoms. Cells were stimulated with
or without HDM (100 mg/ml) and with or without rapamycin
(10 nM) (Sigma-Aldrich, St. Louis, MO). After 96 hours, medium
was collected and analyzed for cytokines by sandwich ELISAs with
a limit of sensitivity of 15.6 pg/ml for IL-4 and IL-17A, 31.25 pg/
ml for IL-5 and 62.5 pg/ml for IL-13 (R & D Systems,
Minneapolis, MN).
Measurement of Plasma IgE
Total plasma IgE was measured using an OptEIA
TM kit (BD
Biosciences Pharmingen, San Diego, CA). Total plasma IgG1 was
measured using an ELISA Quantitation Set from Bethyl
Laboratories, Inc. (Montgomery, TX), whereas total plasma
IgG2a was measured using an ELISA Set from BD Biosciences
Pharminogen (San Diego, CA).
Detection and Quantification of Protein Levels
Whole lungs were removed en bloc, snap frozen in liquid
nitrogen, and stored at 280uC prior to protein extraction. Lungs
were mechanically disrupted using a Brickman mechanical
homogenizer in homogenization buffer (20 mM Tris pH 8.0,
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50 mM NaF, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 100 mM
sodium orthovanadate). Homogenates were snap frozen on dry
ice, thawed, and cleared by centrifugation at 16,0006g for 30 min
at 4uC. Supernatants were assayed for protein content by Bradford
assay. Lung proteins (80 mg) were separated by SDS-PAGE and
transferred to nitrocellulose membrane before immunoblotting
with primary antibodies as indicated. Membranes were incubated
with anti-rabbit or anti-mouse IgG horseradish peroxidase
conjugated antibodies and developed using Super-Signal West
Pico chemiluminescence detection kit (Pierce). Antibodies that
react with S6, phospho-S6, Akt, phospho-Akt, STAT6 and
phospho-STAT6 were from Cell Signaling Technology, Inc.
(Danvers, MA), whereas the antibody that reacted with ß-actin was
from Sigma-Aldrich (St. Louis, MO).
Measurement of Airway Hyperreactivity
Mice were anesthetized with ketamine and xylazine and a 19
gauge beveled metal catheter was inserted into the trachea. Mice
were mechanically ventilated with a tidal volume of 0.2 ml at
2 Hz, while PBS or increasing doses of methacholine (0, 2.5, 5, 7.5
and 10 mg/ml) were administered by nebulization. Airway
resistance was directly measured utilizing an Elan RC Fine Pointe
system (Buxco Research Systems, Wilmington, N.C.). Airway
resistance was recorded at 10 s intervals for 3 min and average
values are presented as cm H20/ml/s.
Statistics
Results are presented as mean 6 SEM. A one-way ANOVA
with a Bonferroni’s multiple comparison test was utilized for all
analyses except for airway hyperreactivity experiments, which
instead utilized a two-way ANOVA with a Bonferroni post-test
test. A P value less than 0.05 was considered significant. Statistical
analyses were performed with GraphPad Prism version 5.0a
(Graphpad Software, Inc., La Jolla, CA).
Results
Paradoxical Effects of Rapamycin on Airway Inflammation
in Murine Models of House Dust Mite-induced Asthma
To induce airway disease, Balb/c mice received daily nasal
administration of HDM (25 mg) for 5 days per week. In the
induction model, mice received rapamycin or vehicle coincident
with the initiation of HDM administration for 3 weeks. In the
treatment model, HDM challenges were performed for 6 weeks,
whereas treatment with rapamycin or vehicle was administered
during weeks 4 through 6 (Figure S1). In the induction model
(Figure 1A), mice that had received rapamycin had a significant
decrease in the total number of bronchoalveolar lavage fluid
(BALF) inflammatory cells, specifically in the number of BALF
eosinophils and lymphocytes. In contrast, in the treatment model
(Figure 1B), rapamycin significantly increased the total number of
BALF inflammatory cells, specifically in the number of eosino-
phils, lymphocytes, neutrophils and macrophages. As shown in
Figure 2, the magnitude of peri-bronchial inflammatory cell
infiltrates reflected the opposite effects of rapamycin on the
number of BALF inflammatory cells in the induction and
treatment models.
The pulmonary expression of Th2 and Th17 cytokines was
assessed to investigate further the mechanisms mediating the
differential effects of rapamycin in the induction and treatment
models of HDM-induced asthma. As shown in Figure 3,
administration of rapamycin prior to the induction of asthma
significantly inhibited lung mRNA levels of canonical Th2 (IL-4
and IL-13) and Th17 (IL17A) cytokines. Treatment of established
asthma with rapamycin, however, did not significantly alter the
HDM-induced increases in lung mRNA levels of IL-4, IL-13 and
IL-17A.
The effect of inhibition of mTOR on the expression of lung
chemokines was also assessed. As shown in Figure 4, administra-
tion of rapamycin in the induction model significantly reduced the
lung mRNA levels of key chemokines that mediate the chemotaxis
of eosinophils and T cells to asthmatic lungs via binding to CCR3,
including CCL11 (eotaxin-1), CCL24 (eotaxin-2) and CCL7
(MCP-3) [16,17,18]. Rapamycin treatment of established asthma,
however, increased mRNA levels of CCL11 and did not affect the
expression of CCL7 or CCL24. Rapamycin did not alter mRNA
levels of CCL17 (TARC) in either the induction or treatment
models of HDM-induced asthma.
These data demonstrate that administration of rapamycin prior
to nasal HDM administration inhibits the induction of airway
inflammation via a mechanism that involves the reduced
expression of Th2- and Th17-type cytokines, as well as C-C
chemokines. Conversely, treatment of established asthma with
rapamycin increased both the number of BALF inflammatory
cells, as well as lung mRNA levels of the C-C chemokine, CCL11.
Paradoxical Effects of Rapamycin on Th2 T Cell Responses
To investigate further the paradoxical effects of rapamycin on
HDM-mediated airway inflammation, we used the induction
model to assess the effects of ex vivo rapamycin on antigen-specific
Th2 cytokine production by T cells isolated from the draining
mediastinal lymph nodes of mice that had previously been
sensitized to HDM in vivo with or without rapamycin administered
by gavage. HDM re-stimulation of mediastinal lymph node cells
recovered from mice that had been challenged with HDM for 3
weeks without in vivo rapamycin treatment showed a significant
reduction in the production of the Th2 cytokines, IL-4, IL-5 and
IL-13 (Figure 5). This result is consistent with a requirement for
mTOR in Th2 cytokine production by HDM-sensitized T cells.
Levels of the Th17 cytokine, IL-17A, were below the limit of
detection of the assay. In contrast, HDM re-stimulation of
mediastinal lymph node cells recovered from HDM-challenged
mice that had been treated with rapamycin both in vivo and ex vivo
showed no reduction in the production of IL-4, IL-5 or IL-13 as
compared to cells that were only treated with rapamycin in vivo.
Taken together, this shows that treatment of rapamycin-naive T
cells with rapamycin decreases the antigen-specific production of
Th2 cytokines, whereas prior exposure of T cells to HDM and
rapamycin for 3 weeks in vivo makes them refractory to the
suppressive effects of ex vivo rapamycin treatment on HDM-
mediated Th2 cytokine production.
Rapamycin has Divergent Effects on IgE Production in
HDM-induced Asthma Disease
Experiments were performed to assess whether rapamycin also
has paradoxical effects on plasma IgE production. As shown in
Figure 6, administration of rapamycin prior to the induction of
HDM-induced asthma markedly attenuated plasma IgE, IgG1
and IgG2a levels, whereas treatment of established airway disease
with rapamycin did not significantly modify plasma levels of IgE,
IgG1 or IgG2a. These results suggest that inhibition of mTOR
signaling with rapamycin inhibited sensitization to HDM allergens
in the induction model, but did not reduce production of IgE,
IgG1 or IgG2a once HDM sensitization had already occurred.
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Hyperplasia
In the induction model, rapamycin administration was associ-
ated with small, but significant, decreases in the number of airways
demonstrating goblet cell hyperplasia and Clca3 (chloride channel
calcium activated 3) mRNA levels, whereas mRNA levels for
Muc5AC (mucin 5, subtypes A and C) were not modified
(Figure 7). In contrast, rapamycin did not modify goblet cell
hyperplasia or mRNA levels of Muc5AC or Clca3 in the treatment
model.
Paradoxical Effect of Rapamycin on HDM-induced Airway
Hyperreactivity
The effect of rapamycin on HDM-induced airway hyperreac-
tivity (AHR) was also assessed. As shown in Figure 8, administra-
tion of rapamycin prior to the induction of HDM-induced asthma
resulted in a small, but significant decrease in AHR, whereas
treatment of established HDM-induced airway disease with
rapamycin was associated with a small, but significant increase
in AHR.
Temporal Association between mTOR Signaling and the
Paradoxical Effects of Rapamycin in Induction and
Treatment Models of HDM-induced Asthma
Western blots of lung proteins were performed to identify the
mechanism by which rapamycin mediates paradoxical effects on
HDM-induced asthma. After 3 weeks in the induction model,
phosphorylation of the S6 ribosomal protein was increased in the
lungs of HDM-challenged mice as compared to saline-challenged
mice (Figure 9). In contrast, after 6 weeks in the treatment model,
S6 phosphorylation was no longer increased in HDM-challenged
mice when compared to saline-challenged mice. In both the
induction and treatment models, rapamycin attenuated S6
phosphorylation in HDM-challenged mice as compared to mice
that received the vehicle control, which demonstrates inhibition of
mTORC1 signaling. In contrast, Akt phosphorylation at serine
473 was neither increased by HDM-challenge nor inhibited by
rapamycin, indicating that rapamycin did not inhibit TORC2
signaling. Lastly, although STAT6 phosphorylation was increased
in HDM-challenged mice in both the induction and treatment
models, it was only inhibited by rapamycin in the induction model.
Figure 1. Paradoxical Effect of Rapamycin on Bronchoalveolar Lavage Fluid Inflammatory Cells in Induction and Treatment Models
of House Dust Mite-induced Asthma. Balb/c mice received daily nasal challenges with HDM (25 mg) 5 days per week. In the induction model
(Panel A), HDM challenges were initiated concurrent with rapamycin administration (3 mg/kg) by gavage 5 days per week for 3 weeks (n=7–10
animals per group). In the treatment model (Panel B), HDM challenges were administered for 6 weeks and rapamycin administration was given during
weeks 4 through 6 (n=12–13 animals per group). * P,0.05 vs. Saline+Vehicle, ** P,0.001. Results are representative of two independent
experiments.
doi:10.1371/journal.pone.0033984.g001
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Rapamycin is a specific and potent inhibitor of mTOR, a highly
conserved and ubiquitous serine-threonine kinase that nucleates
two distinct multi-protein mTOR complexes [19]. mTOR
complex 1 (mTORC1) controls nutrient-sensitive protein synthesis
and cell growth primarily via the initiation of translation and
ribosomal biogenesis, whereas mTORC2 controls cytokinesis and
cell survival via distinct effector kinases [20,21]. Novel adaptor
proteins define the functions of these mTOR complexes.
mTORC1 contains the protein raptor and controls cell growth;
mTORC2 contains the protein rictor and regulates cytoskeletal
rearrangement. Rapamycin specifically blocks signaling via
mTORC1 by binding to the immunophilin FK506-binding
protein 1A (FKBP12), thereby disrupting the interaction between
raptor and mTOR [1]. In contrast, mTORC2, which does not
contain raptor, is thought to be resistant to direct inhibition by
rapamycin. Multiple signaling pathways, such as antigen receptors,
co-stimulatory molecules, growth factors, cytokines, hypoxia,
cellular stress, low cellular energy levels and DNA damage
regulate mTOR signaling. Activated mTORC1 phosphorylates at
Figure 2. Paradoxical Effect of Rapamycin on Lung Histology in Induction and Treatment Models of House Dust Mite-induced
Asthma. Histologic sections of lung were stained with hematoxylin and eosin (H & E) or periodic acid-Schiff (PAS) stains and images obtained at
2006or 10006. Results are representative of 2 independent experiments.
doi:10.1371/journal.pone.0033984.g002
Paradoxical Effects of Rapamycin on Murine Asthma
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e33984least two targets, S6 kinase 1 (S6K1) and the eukaryotic translation
initiation factor-binding protein 1 (EIF4EBP1). Phosphorylation
activates S6K1 and inhibits EIF4EBP1, with resultant enhance-
ment of mRNA translation and cellular growth by augmentation
of the cellular translational apparatus.
Inhibition of mTOR signaling by rapamycin has immunosup-
pressive effects on antigen-presenting cells and T cells, which
thereby modulate adaptive immune responses. For example,
rapamycin inhibits IL-4-dependent dendritic cell (DC) maturation,
fms-like tyrosine 3 kinase ligand (Flt3L)-induced DC mobilization,
as well as co-stimulatory molecule expression, pro-inflammatory
cytokine production and T-cell allostimulation by DCs [1,22].
Rapamycin attenuates DC-mediated antigen uptake and pre-
sentation via the inhibition of macropinocytosis and mannose
receptor-mediated endocytosis [1,23]. mTOR signaling also plays
an important role in modulating the differentiation of effector T
cells. mTOR activation is necessary for the differentiation and
proliferation of Th1, Th2, and Th17 effector T cells, whereas T
cells lacking mTOR differentiate into FOXP3
+ regulatory T cells,
which mediate immunological tolerance [24,25]. Consistent with
its therapeutic use as an immunosuppressant in organ transplant
patients, rapamycin potently inhibits the expansion of T-cell
populations [1]. Based upon its ability to inhibit the DC and
effector T cell functions, rapamycin induces immune tolerance to
solid organ transplants and is utilized clinically to prevent rejection
in kidney transplantation [1]. mTOR inhibition also has effects on
other immune cells that participate in the pathogenesis of asthma
[1]. Rapamycin suppresses B cell responses and antibody pro-
duction, inhibits neutrophil chemotaxis and prevents NKT cell
proliferation.
mTOR signaling also plays an important role in airway smooth
muscle and epithelial cell proliferation. mTORC1-related changes
in the size, proliferation, and survival of smooth muscle or
epithelial cells may contribute to hypertrophy and remodeling of
the airway wall in asthmatics [26,27]. Rapamycin prevents airway
myocyte differentiation into a contractile phenotype via blockade
of the mTORC1/p70 S6 kinase pathway, which may reduce the
intrinsic contractile properties of airway smooth muscle [28].
Rapamycin also inhibits TGF-a-induced pulmonary fibrotic
responses, which could contribute to sub-epithelial fibrosis and
airway remodeling [29]. Similarly, mTOR signaling may modu-
late angiogenesis and lymphangiogenesis, both of which play
important roles in asthma pathogenesis [30,31]. Inhibition of
mTOR blocks the synthesis of vascular endothelial growth factor
(VEGF), an angiogenesis factor that induces an asthma phenotype
in mice [32,33]. mTOR physically interacts with the transcription
factor HIF-1a, which regulates the expression of multiple
angiogenesis genes [34]. Furthermore, mechanical strain of airway
Figure 3. Paradoxical Effect of Rapamycin on Lung Th2 and Th17 Cytokine Expression in Induction and Treatment Models of House
Dust Mite-induced Asthma. Quantification of lung mRNA levels for IL-4, IL-13, and IL-17A by qRT-PCR presented as relative mRNA expression.
Results for the induction experiment are shown in Panel A (n=6–8 animals per group, * P,0.05, HDM+Vehicle vs. HDM+Rapamycin), while results for
the treatment experiment are shown in Panel B (n=6–10 animals per group, * P,0.001). Results are representative of 2 independent experiments.
doi:10.1371/journal.pone.0033984.g003
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mTOR and ERK pathways, which may thereby contribute to
angiogenesis in asthma [32].
Based upon the important role of mTOR signaling in
inflammatory and remodeling responses, we investigated whether
rapamycin could be utilized to modify the pathogenic manifesta-
tions of asthma as well as provide new insights into disease
pathogenesis. Here, we show that rapamycin has paradoxical
effects depending on whether it is administered prior to the
induction of HDM-induced asthma or as a treatment during the
effector phase of HDM-induced asthma. Administration of
rapamycin coincident with HDM exposure significantly attenuat-
ed eosinophilic and lymphocytic airway inflammation, which was
mediated by the reduced expression of Th2- and Th17-type
cytokines and C-C chemokines, as well as production of IgE, IgG1
and IgG2a. This is consistent with the role of mTOR in mediating
the differentiation of CD4
+ T cells into Th2 and Th17 subsets
[24,35]. Rapamycin also reduced the induction of AHR and
goblet cell hyperplasia.
In contrast, treatment of established HDM-induced asthma
with rapamycin augmented airway inflammatory responses, as
indicated by significant increases in the number of BALF
eosinophils, lymphocytes and neutrophils. Similarly, treatment of
established HDM-induced asthma with rapamycin worsened
AHR and did not reduce goblet cell hyperplasia or IgE
production. Taken together, these results demonstrate that
inhibition of mTOR signaling by rapamycin represents a ‘‘molec-
ular switch’’ with divergent effects on asthma pathogenesis that are
dependent upon the temporal relationship between rapamycin
administration and allergen sensitization. When administered
concurrent with HDM, rapamycin blocked allergic sensitization
and the induction of the key manifestations of asthma, but when
Figure 4. Paradoxical Effect of Rapamycin on Lung C-C Chemokine Expression in Induction and Treatment Models of House Dust
Mite-induced Asthma. Quantification of lung mRNA levels for CCL11, CCL24, CCL7 and CCL17 by qRT-PCR presented as relative mRNA expression.
Results for the induction experiment are shown in Panel A (n=6 animals per group, * P,0.01), while results for the treatment experiment are shown
in Panel B (n=5–10 animals per group, * P,0.05). Results are representative of 2 independent experiments.
doi:10.1371/journal.pone.0033984.g004
Figure 5. Effects of Rapamycin on Mediastinal Lymph Node Th2 Cytokine Production. Mediastinal lymph nodes from HDM-challenged
mice that had or had not been treated with rapamycin concurrent with HDM stimulation for 3 weeks (induction model) were cultured ex vivo with or
without HDM re-stimulation and/or rapamycin. The amount of IL-4, IL-5 and IL-13 released into the medium was quantified by ELISA (* P,0.05, n=5–
6). Results are representative of two independent experiments.
doi:10.1371/journal.pone.0033984.g005
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exacerbated disease severity as evidenced by enhanced airway
inflammation and AHR.
The mechanism underlying the paradoxical effects of rapamy-
cin in the induction and treatment models of HDM-induced
asthma may in part have reflected the temporal association
between HDM challenge and activation of mTOR signaling
pathways. Activation of mTORC1 signaling was assessed by
phosphorylation of its downstream target, the S6 ribosomal
protein. S6 phosphorylation was increased after 3 weeks of
HDM challenge in the induction model, but returned to levels
similar to those of saline-challenged mice at 6 weeks in the
treatment model. Consistent with this finding, inhibition of
mTOR signaling with rapamycin attenuated HDM-induced
asthma only in the induction model when mTOR signaling was
up-regulated, but not in the treatment model when mTOR
Figure 6. Paradoxical Effect of Rapamycin on Plasma Immunoglobulin Levels in House Dust Mite-induced Asthma. Plasma levels of
IgE, IgG1 and IgG2a were quantified. Results for the induction experiment are shown in Panels A, C and E, while results for the treatment experiment
are shown in Panels B, D and F (n=8–20 animals per group, * P,0.05 vs. Saline+Vehicle, ** P,0.001).
doi:10.1371/journal.pone.0033984.g006
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e33984signaling was no longer increased. Changes in STAT6 phosphor-
ylation paralleled the effects of rapamycin on HDM-induced
asthma. Furthermore, Akt phosphorylation was neither up-
regulated by HDM challenge nor inhibited by rapamycin, which
Figure 7. Paradoxical Effect of Rapamycin on Goblet Cell Hyperplasia in House Dust Mite-induced Asthma. Quantification of lung
mRNA levels for Muc5AC and Clca3 by qRT-PCR are presented as relative mRNA expression. Results for the induction experiment are shown in Panel A
(n=6 animals per group, * P,0.01), while the results for the treatment experiment are shown in Panel B (n=5–6 animals per group, P=NS). Results
are representative of 2 independent experiments. Goblet cell hyperplasia is presented as the percentage of airways containing PAS-positive cells
(n=8–10 animals per group, * P,0.001). 35.360.6 airways were inspected in each mouse.
doi:10.1371/journal.pone.0033984.g007
Figure 8. Paradoxical Effect of Rapamycin on Airway Hyperreactivity in House Dust Mite-induced Asthma. Airway resistance (cm H20/
ml/s) was directly measured following administration of increasing doses of nebulized methacholine. Results for the induction experiment are shown
in Panel A (n=10 animals per group, * P,0.05), while results form the treatment experiment are shown in Panel B (n=9–10 animals per group, *
P,0.05). Results are representative of 2 independent experiments.
doi:10.1371/journal.pone.0033984.g008
Paradoxical Effects of Rapamycin on Murine Asthma
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modulate HDM-induced asthma in this model.
We also found that rapamycin had paradoxical effects on Th2
cytokine production by T cells. The ex vivo treatment of
mediastinal lymph node cells from HDM-challenged, rapamy-
cin-naive mice with rapamycin attenuated the production of Th2
cytokines, which is consistent with the ability of rapamycin to
inhibit the induction of allergen-mediated Th2-type inflammatory
responses by HDM-sensitized T cells. In contrast, ex vivo
rapamycin treatment of mediastinal lymph node cells from
HDM-challenged mice that had already been exposed in vivo to
rapamycin did not suppress Th2 cytokine production. This shows
that prior rapamycin treatment renders mediastinal T cells
refractory to the suppressive effects of rapamycin on Th2 cytokine
production. Thus, these data are additional evidence supporting
the context-dependent effects of mTOR inhibition on Th2
cytokine production.
Our findings are consistent with prior reports that showed
paradoxical pro-inflammatory effects of rapamycin. For example,
although rapamycin has immunosuppressive effects and is utilized
clinically to prevent kidney transplant rejection, its use has been
complicated by the development of a lymphocytic interstitial
pneumonitis [36]. Glomerulonephritis and anemia secondary to
a chronic inflammatory state have also been observed in patients
treated with mTOR inhibitors, which is consistent with a pro-
inflammatory role for rapamycin in some patients [37,38,39].
Similarly, in a murine model of cigarette smoke-induced lung
inflammation, rapamycin decreased cigarette smoke-induced
phosphorylation of NF-kappaB p65 [40]. In contrast, mice
exposed to room air had an increase in BALF macrophages and
neutrophils, NF-kappaB p65 phosphorylation and alveolar lung
cell apoptosis. At the cellular level, mTOR can physically interact
with NF-kappaB or STAT1, both of which are associated with
airway inflammation in asthma. Furthermore, in dendritic cells
and epithelial cells, reduced mTOR activity has been associated
with enhanced NF-kappaB and STAT1 activity [41,42,43].
In conclusion, our results demonstrate that inhibition of mTOR
signaling with rapamycin has paradoxical effects on the patho-
genesis of HDM-induced asthma that are dependent upon the
temporal relationship between rapamycin administration and the
activation of mTOR signaling pathways. Rapamycin attenuated
the manifestations of HDM-induced asthma after 3 weeks in the
induction model when mTOR signaling was increased, but
exacerbated HDM-induced asthma after 6 weeks in the treatment
model, when mTOR signaling had returned to basal levels.
Furthermore, our findings suggest that rapamycin might not
represent an effective treatment approach for HDM-induced
asthma.
Supporting Information
Figure S1 House dust mite (HDM) or saline was
administered daily 5 days per week via an intranasal
route for 3 weeks in the induction model (A) or 6 weeks
in the treatment model (B). Similarly, mice received
rapamycin or vehicle by oral gavage 5 days per week for 3 weeks
in the induction model (A) or during weeks 4 through 6 in the
treatment model (B).
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